Dr. Francesco Cottone, PhD - Italian Group for Adult Hematologic Diseases (GIMEMA) Data Center and Health Outcomes Research Unit, Rome, Italy

Dr. Francesco Cottone

PhD

Italian Group for Adult Hematologic Diseases (GIMEMA) Data Center and Health Outcomes Research Unit, Rome, Italy

Rome | Italy

Main Specialties: Statistics

Additional Specialties: Clinical trials, Patient-Reported Outcomes, Quality of life

ORCID logohttps://orcid.org/0000-0001-6240-8317

Dr. Francesco Cottone, PhD - Italian Group for Adult Hematologic Diseases (GIMEMA) Data Center and Health Outcomes Research Unit, Rome, Italy

Dr. Francesco Cottone

PhD

Introduction

Primary Affiliation: Italian Group for Adult Hematologic Diseases (GIMEMA) Data Center and Health Outcomes Research Unit, Rome, Italy - Rome , Italy

Specialties:

Additional Specialties:

Education

May 2008
University Roma Tre
PhD

Experience

Apr 2008 - Mar 2019
GIMEMA (Italian Group for Adult Hematologic Diseases)
Statistician
Health Outcomes Research Unit
Oct 2017
Outstanding poster presentation award winner

24th Annual Conference of the International Society for Quality of Life Research, Philadelphia, Pennsylvania, USA.
Oct 2013
Outstanding poster abstract award

20th Annual Conference of the International Society for Quality of Life Research, Miami, Florida, USA.
Feb 2012
Statistics in Medicine - Journal of Applied Statistics - Journal of Statistical Software - Health and Quality of Life Outcomes - BMC Cancer - Leukemia Research - Disability and Rehabilitation - BioMed Research International
Reviewer
https://publons.com/author/726167/francesco-cottone
Jan 2012
Editorial board of "Health and Quality of Life Outcomes” Journal.
Statistical advisor
http://www.hqlo.com/about/edboard
Oct 2011
Outstanding poster award

18th Annual Conference of the International Society for Quality of Life Research, Denver, Colorado, USA.

Publications

30Publications

364Reads

213Profile Views

86PubMed Central Citations

Clinician-reported symptomatic adverse events in cancer trials: are they concordant with patient-reported outcomes?

J Comp Eff Res 2019 03 6. Epub 2019 Mar 6.

Italian Group for Adult Hematologic Diseases (GIMEMA), Data Center & Health Outcomes Research Unit, Rome, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2217/cer-2018-0092DOI Listing
March 2019
2 Reads

Propensity score methods and regression adjustment for analysis of nonrandomized studies with health-related quality of life outcomes.

Pharmacoepidemiol Drug Saf 2019 Feb 19. Epub 2019 Feb 19.

Italian Group for Adult Hematologic Diseases (GIMEMA) Data Center and Health Outcomes Research Unit, Rome, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/pds.4756DOI Listing
February 2019
1 Read
2.939 Impact Factor

Time for patient reported outcomes assessment in routine hematology practice: the case of chronic myeloid leukemia.

Expert Rev Hematol 2019 Jan 14;12(1):1-3. Epub 2018 Nov 14.

a Data Center and Health Outcomes Research Unit , Italian Group for Adult Hematologic Diseases (GIMEMA) , Rome , Italy.

View Article

Download full-text PDF

Source
https://www.tandfonline.com/doi/full/10.1080/17474086.2019.1
Publisher Site
http://dx.doi.org/10.1080/17474086.2019.1547189DOI Listing
January 2019
5 Reads

Modeling strategies to improve parameter estimates in prognostic factors analyses with patient-reported outcomes in oncology.

Qual Life Res 2019 Jan 18. Epub 2019 Jan 18.

Data Center and Health Outcomes Research Unit, Italian Group for Adult Hematologic Diseases (GIMEMA), Rome, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11136-018-02097-2DOI Listing
January 2019
2 Reads
2.486 Impact Factor

Distribution- and anchor-based methods to determine the minimally important difference on patient-reported outcome questionnaires in oncology: a structured review.

Health Qual Life Outcomes 2018 Dec 11;16(1):228. Epub 2018 Dec 11.

Methodology and Quality of Life in Oncology Unit (INSERM UMR 1098), University Hospital of Besançon, Besançon, France.

View Article

Download full-text PDF

Source
https://hqlo.biomedcentral.com/articles/10.1186/s12955-018-1
Publisher Site
http://dx.doi.org/10.1186/s12955-018-1055-zDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6288886PMC
December 2018
10 Reads
2.120 Impact Factor

Evaluating methodological quality of Prognostic models Including Patient-reported HeAlth outcomes iN oncologY (EPIPHANY): a systematic review protocol.

BMJ Open 2018 Oct 24;8(10):e025054. Epub 2018 Oct 24.

Data Center and Health Outcomes Research Unit, Italian Group for Adult Hematologic Diseases (GIMEMA), Rome, Italy.

View Article

Download full-text PDF

Source
http://bmjopen.bmj.com/lookup/doi/10.1136/bmjopen-2018-02505
Publisher Site
http://dx.doi.org/10.1136/bmjopen-2018-025054DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6224737PMC
October 2018
13 Reads
2.063 Impact Factor

Patient-reported outcome assessment in acute leukemias: Moving beyond the barriers.

Cancer 2018 Jul 30;124(14):3066-3067. Epub 2018 Apr 30.

Department of Biomedicine and Prevention, University of Rome Tor Vergata, Rome, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/cncr.31521DOI Listing
July 2018
1 Read
4.890 Impact Factor

Psychological well-being and social support in chronic myeloid leukemia patients receiving lifelong targeted therapies.

Support Care Cancer 2016 12 23;24(12):4887-4894. Epub 2016 Jul 23.

Department of Hematology-Oncology, University of Bologna, S. Orsola-Malpighi Hospital, Bologna, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00520-016-3344-6DOI Listing
December 2016
12 Reads
1 Citation
2.364 Impact Factor

Pushing the boundaries of care in myelodysplastic syndromes: Physical exercise to improve fatigue and health-related quality of life outcomes.

Leuk Res 2016 10 9;49:36-7. Epub 2016 Aug 9.

Italian Group for Adult Hematologic Diseases (GIMEMA), Data Center and Health Outcomes Research Unit, Rome, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.leukres.2016.08.003DOI Listing
October 2016
2 Reads
2.351 Impact Factor

The impact of comorbidity on health-related quality of life in elderly patients with chronic myeloid leukemia.

Ann Hematol 2016 Jan 7;95(2):211-9. Epub 2015 Nov 7.

Department of Hematology-Oncology, S. Orsola-Malpighi Hospital, University of Bologna, Bologna, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00277-015-2541-6DOI Listing
January 2016
12 Reads
2.634 Impact Factor

Time to improve health-related quality of life outcomes in patients with acute promyelocytic leukemia.

Blood 2015 Nov 9;126(22):2523-4. Epub 2015 Oct 9.

Dipartimento di Biomedicina e Prevenzione, Università Tor Vergata, Roma, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1182/blood-2015-07-658922DOI Listing
November 2015
5 Reads
10.452 Impact Factor

Reply to M. Koehler et al.

J Clin Oncol 2015 Mar 17;33(9):1091-2. Epub 2015 Feb 17.

Università Tor Vergata; Fondazione Santa Lucia, Rome, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2014.60.3597DOI Listing
March 2015
2 Reads
18.430 Impact Factor

Randomized phase III trial of retinoic acid and arsenic trioxide versus retinoic acid and chemotherapy in patients with acute promyelocytic leukemia: health-related quality-of-life outcomes.

J Clin Oncol 2014 Oct 22;32(30):3406-12. Epub 2014 Sep 22.

Fabio Efficace, Franco Mandelli, Francesco Cottone, and Marco Vignetti, Gruppo Italiano Malattie Ematologiche dell'Adulto; Giuseppe Avvisati, Università Campus Biomedico; Massimo Breccia, Università "La Sapienza,"; Simona Sica, Università Cattolica Sacro Cuore; Sergio Amadori and Francesco Lo-Coco, Università Tor Vergata; Francesco Lo-Coco, Fondazione Santa Lucia, Roma; Felicetto Ferrara, Ospedale Cardarelli; Olimpia Finizio, Ospedale Cardarelli, Napoli; Eros Di Bona, Ospedale San Bortolo, Vicenza; Giorgina Specchia, Università di Bari, Bari; Alessandro Levis, Ospedale SS Antonio e Biagio, Alessandria; Maria Grazia Kropp, Azienda Ospedaliera Pugliese Ciaccio, Catanzaro; Giuseppe Fioritoni, Ospedale Civile, Pescara; Elisa Cerqui, Spedali Civili, Brescia, Italy; Richard F. Schlenk, University of Ulm, Ulm; and Uwe Platzbecker, Universitatsklinikum Carl Gustav Carus, Dresden, Germany.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2014.55.3453DOI Listing
October 2014
49 Reads
16 Citations
18.430 Impact Factor

Randomized Phase III Trial of Retinoic Acid and Arsenic Trioxide Versus Retinoic Acid and Chemotherapy in Patients With Acute Promyelocytic Leukemia: Health-Related Quality-of-Life Outcomes.

JCO 2014 Sep 22. Epub 2014 Sep 22.

Journal of Clinical Oncology

Purpose A randomized clinical trial compared efficacy and toxicity of standard all-trans-retinoic acid (ATRA) plus chemotherapy versus ATRA plus arsenic trioxide in patients with newly diagnosed, low- or intermediate-risk acute promyelocytic leukemia (APL). Here, we report health-related quality-of-life (HRQOL) results. Patients and Methods HRQOL was a secondary end point of this trial. The European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire–Core 30 was used to assess HRQOL at end of induction and after consolidation therapy. All analyses were based on 156 patients who received at least one dose of treatment, with groups defined according to randomly assigned treatment. Primary analysis was performed, estimating mean HRQOL score over time and differences between treatment arms using a linear mixed model. Results Overall, 162 patients age 18 to 70 years were enrolled. Of these, 150 and 142 patients were evaluable for HRQOL after induction therapy and third consolidation course, respectively. Overall compliance with HRQOL forms was 80.1%. The largest difference, favoring patients treated with ATRA plus arsenic trioxide, was found for fatigue severity (mean score difference, 9.3; 95% CI, -17.8 to -0.7; P = .034) at end of induction therapy. This difference was also clinically relevant. HRQOL differences between treatment arms at end of consolidation showed that for several scales, differences between treatment arms were marginal. Conclusion Overall, current HRQOL findings further support the use of ATRA plus arsenic trioxide as preferred first-line treatment in patients with low- or intermediate-risk APL.

View Article
September 2014
2 Reads

Profiling chronic myeloid leukemia patients reporting intentional and unintentional non-adherence to lifelong therapy with tyrosine kinase inhibitors.

Leuk Res 2014 Mar 30;38(3):294-8. Epub 2013 Jul 30.

Department of Cellular Biotechnologies and Hematology, University of Rome "Sapienza", Rome, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.leukres.2013.07.003DOI Listing
March 2014
10 Reads
7 Citations
2.351 Impact Factor

Preference for Involvement in Treatment Decisions and Request for Prognostic Information in Newly Diagnosed Patients with Higher-Risk Myelodysplastic Syndromes.

Efficace F, Gaidano G, Sprangers M, Cottone F, Breccia M, Voso MT, Caocci G, Stauder R, Di Tucci AA, Sanpaolo G, Selleslag D, Angelucci E, Platzbecker U, Mandelli F, Annals of oncology : official journal of the European Society for Medical Oncology / ESMO, 2014, vol. 25, no. 2, pp. 447-454

http://europepmc.org/abstract/med/24478321

View Article
February 2014
6 Reads

The added value of propensity score matching when using health-related quality of life reference data.

Stat Med 2013 Dec 5;32(29):5119-32. Epub 2013 Jun 5.

Italian Group for Adult Hematologic Diseases (GIMEMA) Data Center and Health Outcomes Research Unit, Rome, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/sim.5868DOI Listing
December 2013
12 Reads
2.040 Impact Factor

Chronic fatigue is the most important factor limiting health-related quality of life of chronic myeloid leukemia patients treated with imatinib

Leukemia 2013 Jul;27(7):1511-19. Epub 2013 Mar 15.

Leukemia

Health-related quality of life (HRQOL) is an important goal of therapy for chronic myeloid leukemia (CML) patients treated with current molecular-targeted therapies. The main objective of this study was to investigate factors associated with long-term HRQOL outcomes of CML patients receiving imatinib. Analysis was performed on 422 CML patients recruited in an observational multicenter study. HRQOL was assessed with the Medical Outcomes Study 36-Item Short-Form Health Survey (SF-36). Key socio-demographic and clinical data were investigated for their association with HRQOL outcomes. Chronic fatigue and social support were also investigated. Univariate and multivariate linear regression analyses were used to identify independent factors associated with HRQOL outcomes. Fatigue was the only variable showing an independent and consistent association across all physical and mental HRQOL outcomes (P<0.01). Differences between patients reporting low versus high fatigue levels were more than eight and seven times the magnitude of a clinically meaningful difference, respectively, for the role physical (Δ=70 points) and emotional scale (Δ=63 points) of the SF-36. Fatigue did not occur as an isolated symptom and was most highly correlated with musculoskeletal pain (r=0.511; P<0.001) and muscular cramps (r=0.448; P<0.001). Chronic fatigue is the major factor limiting HRQOL of CML patients receiving imatinib.

View Article
July 2013
2 Reads

Tyrosine-kinase inhibitors and patient-reported outcomes in chronic myeloid leukemia: a systematic review.

Leuk Res 2013 Feb 22;37(2):206-13. Epub 2012 Nov 22.

Italian Group for Adult Hematologic Diseases, GIMEMA, Data Center and Health Outcomes Research Unit, Rome, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.leukres.2012.10.021DOI Listing
February 2013
6 Reads
5 Citations
2.351 Impact Factor

Investigating factors associated with adherence behaviour in patients with chronic myeloid leukemia: an observational patient-centered outcome study

BJC 2012 Sep;107(6):904-909.Epub 2012 August 7

British Journal of Cancer

Background: Optimal adherence to imatinib therapy is of paramount importance to maximise treatment effectiveness in patients with chronic myeloid leukaemia (CML). The main objective of this study was to investigate patient-reported personal factors associated with adherence behaviour. Methods: Analysis was conducted on 413 CML patients receiving long-term therapy with imatinib. Adherence behaviour was measured with the Morisky Medication Adherence Scale and personal factors investigated included: quality of life, perceived social support, fatigue, symptom burden, psychological wellbeing and desire for additional information. Key socio-demographic and treatment-related factors were also taken into account. Univariate and multivariate logistic regression analyses were used to investigate factors associated with optimal adherence to therapy. Results: In all, 53% of patients reported an optimal adherence behaviour. The final multivariate model retained the following variables as independent predictors of optimal adherence to therapy: desire for more information (ref. no), odds ratio (OR)=0.43 (95% confidence interval (CI), 0.29–0.66; P<0.001), social support (higher score representing greater support), OR=1.29 (95% CI, 1.11–1.49; P<0.001) and concomitant drug burden (ref. no), OR=1.82 (95% CI, 1.18–2.80; P=0.006). Conclusion: This study suggests that a higher level of social support, satisfaction with information received and concomitant drug burden are the main factors associated with greater adherence to long-term imatinib therapy.

View Article
September 2012
2 Reads

Top co-authors

Fabio Efficace
Fabio Efficace

Data Center and Health Outcomes Research Unit

25
Franco Mandelli
Franco Mandelli

Data Center and Health Outcomes Research Unit

12
Massimo Breccia
Massimo Breccia

Sapienza University

9
Marco Vignetti
Marco Vignetti

Data Center and Health Outcomes Research Unit

8
Michele Baccarani
Michele Baccarani

University of Bologna

5
Uwe Platzbecker
Uwe Platzbecker

University Hospital Carl Gustav Carus

5
Gianantonio Rosti
Gianantonio Rosti

Institute of Hematology "L. and A. Seràgnoli"

5
Emanuele Angelucci
Emanuele Angelucci

Hematology Unit

5
Giovanni Caocci
Giovanni Caocci

Università di Cagliari

4
Amelie Anota
Amelie Anota

Aix-Marseille Université

4

Followers